BP
GDRX icon

Ballentine Partners’s GoodRx Holdings GDRX Stock Holding History

Ballentine Partners’s Portfolio GDRX Stock Details GDRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-69,167
Closed -$293K – 1037
2025
Q3 		$293K Buy
69,167
+44,793
+184% +$197K ﹤0.01% 722
2025
Q2 		$121K Buy
+24,374
New +$106K ﹤0.01% 928

Other funds holding GDRX

FPM
Francisco Partners Management San Francisco, California $292M AUM 34.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SLG
Silver Lake Group Menlo Park, California $3.68B AUM 7.22% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PTC
Petrus Trust Company Dallas, Texas $915M AUM 2.95% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PGCM
Prescott Group Capital Management Tulsa, Oklahoma $1B AUM 51.95% 1-Year Est. Return

Ballentine Partners's GDRX Position: Q4 2025 in Review

Ballentine Partners sold out of GoodRx Holdings (GDRX) in Q4 2025, closing a stake of 69,167 shares — an estimated $293K sold.

Ballentine Partners first reported a position in GDRX in Q2 2025 and held it in 2 quarters. The position peaked at $293K in Q3 2025. 183 funds tracked by Wall St. Rank hold GDRX as of Q4 2025.

  • Ballentine Partners reported no remaining GoodRx Holdings position as of Q4 2025 after selling out during the quarter.
  • Ballentine Partners sold 69,167 GoodRx Holdings shares in Q4 2025, an estimated $293K.
  • Ballentine Partners first reported a position in GoodRx Holdings in Q2 2025 and held it in 2 quarters.
  • Ballentine Partners's GoodRx Holdings position peaked at $293K in Q3 2025.
  • 183 funds tracked by Wall St. Rank held GoodRx Holdings as of Q4 2025.

Based on Ballentine Partners's 13F filing for Q4 2025, filed 3 Feb 2026.